At the intersection of computation and biology, Models & Molecules explores how data, algorithms, and science come together to design the medicines of tomorrow.
Each episode features candid conversations with the people shaping this transformation, from pharma R&D leaders to computational biologists and AI innovators.
Produced by ENPICOM (https://enpicom.com/models-molecules), Models & Molecules offers a rare look behind the buzzwords of AI-driven discovery, uncovering the practical realities, lessons learned, and moments of insight that emerge when biology meets computation.
Melody Shahsavarian | Agentic AI and the Digital Transformation of Pharma R&D
In this special in-person episode, recorded in San Diego, we sit down with Melody Shahsavarian, Senior Director of Data Strategy and Digital Transformation at Eli Lilly. Before Lilly, she led NGS and AI for biologics discovery at Sanofi, where she moved from antibody discovery researchinto the data and digital side of biologics R&D.
Melody discusses the role of agentic AI in pharma R&D: why scientists have adopted it so readily, where deterministic automation ends and agents begin, and what validation and governance should look like. She makes the case for specialized agents with deep domain context, and closes with her contrarian take: not every problem needs an agent.
11 Aug 2026
Iddo Weiner | Data, moats, and open science: Building scalable AI applications for bio
In this episode, we sit down with Iddo Weiner, co-founder and CSO of Converge Bio, to discuss the evolving biotech and AI landscape: where models, data, and scale actually create advantage, why delivering AI services calls for a customer-centric approach, and how openness pays off for scientists and businesses alike.
2 Jun 2026
Talip Uçar | Inside Boltz's open-source bet on the future of AI-driven drug discovery
When an AI model generates an image, you can tell at a glance whether it's any good. In life sciences, that feedback loop is fragmented across data, modelling, experiments, and the clinic, and signal gets lost at every handoff. In this episode, we sit down with Talip Uçar, founding member of Boltz, to discuss why data is the real competitive advantage, why pharma needs a tech-first mindset to make AI work, and why a unified data fabric remains the field's missing layer.
Watch the full conversation and read the transcript → https://enpicom.com/models-molecules/talip-ucar-inside-boltzs-open-source-bet-on-the-future-of-ai-driven-drug-discovery/ (https://enpicom.com/models-molecules/talip-ucar-inside-boltzs-open-source-bet-on-the-future-of-ai-driven-drug-discovery/ )
14 Apr 2026
Steve Comeau | From novel binder design to the realities of AI in complex therapeutics
Generative models can now propose novel antibody sequences from antigen structure alone, but how far does that actually get you? In this episode, we sit down with Principal Scientist Steve Comeau to discuss what current models can realistically deliver, where the data falls short, and why the harder problems are still ahead of us.
Read the full conversation: https://enpicom.com/models-molecules/steve-comeau-from-novel-binder-design-to-the-realities-of-ai-in-complex-therapeutics/ (https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/)
3 Mar 2026
Jiwon Kim | From lab-in-the-loop to zero-shot: The role of cloud and AI agents
Jiwon Kim, Product Lead at AWS AI Life Sciences, joins Models & Molecules to break down pharma’s digital shift: where cloud and software are becoming core infrastructure for modern drug discovery.
We touch upon the potential of agentic AI, why zero-shot models are the future, why lab in the loop is the essential bridge for getting there.
Read the full conversation: https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/ (https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/)
28 Jan 2026
Do Soon Kim | Navigating the convergence of tech and pharma
In this episode of Models & Molecules, Do Soon Kim, Head of Product at Xaira Therapeutics, discusses his journey in the biotech and AI sectors, emphasizing the importance of effective communication in fostering collaboration between different scientific disciplines. The conversation explores the potential of machine learning to reshape our understanding of intelligence and moving beyond the limits of human intuition to decode complex biology.
Read the full interview: https://enpicom.com/models-molecules/do-soon-kim-navigating-the-convergence-of-tech-and-pharma/ (https://enpicom.com/models-molecules/do-soon-kim-navigating-the-convergence-of-tech-and-pharma/)
16 Dec 2025
Jaap Goudsmit | From rabies to COVID: Antibody discovery in the age of AI
In this episode of Models & Molecules, Jaap Goudsmit, MD, PhD, immunologist, epidemiologist, and one of the scientific forces behind Crucell, the Dutch biotech acquired by Johnson & Johnson, explores the critical evolution of antibody research. Jaap reflects on the journey from traditional discovery to the complexities of modern drug development, highlighting the transformative role of AI and why high-quality training data is essential for the next generation of therapeutics.
Read the full conversation: https://enpicom.com/models-molecules/jaap-goudsmit-from-rabies-to-covid-antibody-discovery-in-the-age-of-ai/
4 Nov 2025
René Hoet | Taking risks and driving innovation in biopharma
In this episode of Models & Molecules, René Hoet reflects on game-changing technologies like phenotypic screening, the unique innovation dynamics of small biotechs versus large pharma, and the real-world impact of AI in antibody discovery. We touch upon bridging academia and industry and discuss why taking calculated risks is essential for the next breakthroughs in drug discovery.
Read the full conversation here (https://enpicom.com/models-molecules/rene-hoet-taking-risks-and-driving-innovation-biopharma/).
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
5.0 / 5
8 ratings
Contact Models & Molecules
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
